No significant difference were noted in the percentage of CD3+CD45+ cells, CD16+CD56+ NK cells, CD19+ B cells, CD3+CD4+ Th cells, CD3+CD8+ CTL and the ratio of CD4+/CD8+ T cells amongst the tumor stage (Supplementary Fig. 3). This evidence concerns the gene CD8A and neoplasm.